Use of bisphosphonates and risk of breast cancer

Calcified Tissue International

Volumn 88, Issue 4, 2011, Pages 255-262

  Vestergaard, Peter ^a   Fischer, Lone ^a   Mele, Marco ^a   Mosekilde, Leif ^a   Christiansen, Peer ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Bisphosphonate; Breast cancer; Raloxifene; Register study

Indexed keywords

ALENDRONIC ACID; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; ZOLEDRONIC ACID;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXPOSURE; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION;

ADULT; AGE FACTORS; AGED; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; DENMARK; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MIDDLE AGED; ODDS RATIO; OSTEOPOROSIS; RISK;

EID: 79954424459     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-011-9463-7     Document Type: Article

References (40)

1. J Body I Diel M Lichinitzer A Lazarev M Pecherstorfer R Bell, et al. 2004 Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies Br J Cancer 90 1133 1137 15026791 10.1038/sj.bjc.6601663 1:CAS:528:DC%2BD2cXitV2rs7w%3D (Pubitemid 38496803)
2. F Cleton A Holten-Verzantvoort O Bijvoet 1989 Effect of long-term bisphosphonate treatment on morbidity due to bone metastases in breast cancer patients Recent Results Cancer Res 116 73 78 2669067 1:STN:280: DyaL1Mzks1CjsA%3D%3D
3. D Santini B Vincenzi S Galluzzo F Battistoni L Rocci O Venditti, et al. 2007 Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients Clin Cancer Res 13 4482 4486 17671133 10.1158/1078-0432.CCR-07-0551 1:CAS:528:DC%2BD2sXotlGqtb4%3D (Pubitemid 47219717)
4. K Mystakidou E Katsouda E Parpa A Kelekis A Galanos L Vlahos 2005 Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline Med Oncol 22 195 201 15965284 10.1385/MO:22:2:195 1:CAS:528:DC%2BD2MXos1anurc%3D (Pubitemid 41003454)
5. F Daubiné C Le Gall J Gasser J Green P Clézardin 2007 Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis J Natl Cancer Inst 99 322 330 17312309 10.1093/jnci/djk054 (Pubitemid 47073494)
6. M Gnant B Mlineritsch W Schippinger G Luschin-Ebengreuth S Pöstlberger C Menzel, et al. 2009 Endocrine therapy plus zoledronic acid in premenopausal breast cancer N Engl J Med 360 679 691 19213681 10.1056/NEJMoa0806285 1:CAS:528:DC%2BD1MXhvVyisbk%3D
7. Rennert G, Pinchev M, Rennert H (2009) Use of bisphosphonates and risk of postmenopausal breast cancer. Presented at the 32nd annual San Antonio Breast Cancer Symposium, San Antonio, December 9-13, 2009. Cancer Res 69 Suppl 1
8. Chlebowski R, Chen Z, Cauley J, Rodabough R, McTiernan A, Lane D, et al. (2009) Oral bisphosphonates and breast cancer: prospective results from the Women's Health Initiative (WHI). Presented at the 32nd annual San Antonio Breast Cancer Symposium, San Antonio, December 9-13, 2009. Cancer Res 69 Suppl 1
9. A Brufsky N Bundred R Coleman R Lambert-Falls R Mena P Hadji, et al. 2008 Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole Oncologist 13 503 514 18515735 10.1634/ theoncologist.2007-0206 1:CAS:528:DC%2BD1cXotFait70%3D (Pubitemid 351872868)
10. Writing Group for the Women's Health Initiative Investigators 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial JAMA 288 321 333 10.1001/jama.288.3.321
11. V Beral Million Women Study Collaborators 2003 Breast cancer and hormone-replacement therapy in the Million Women Study Lancet 362 419 427 12927427 10.1016/S0140-6736(03)14596-5 1:CAS:528:DC%2BD3sXmt1ajsrw%3D (Pubitemid 36999703)
12. The Women's Health Initiative Steering Committee 2004 Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial JAMA 291 1701 1712 10.1001/jama.291.14.1701 (Pubitemid 38489892)
13. D Torgerson S Bell-Syer 2001 Hormone replacement therapy and prevention of nonvertebral fractures. A meta-analysis of randomized trials JAMA 285 2891 2897 11401611 10.1001/jama.285.22.2891 1:CAS:528:DC%2BD3MXkvVOnt74%3D (Pubitemid 32537354)
14. D Torgerson S Bell-Syer 2001 Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials BMC Musculoskelet Disord 2 7 10 11716794 10.1186/1471-2474-2-7 1:STN:280:DC%2BD3szhslGiug%3D%3D
15. P Vestergaard L Mosekilde 2003 Fracture risk associated with smoking-a meta-analysis J Intern Med 254 572 583 14641798 10.1111/j.1365-2796.2003.01232.x 1:STN:280:DC%2BD3srmvFShtA%3D%3D (Pubitemid 37521854)
16. C Magnusson S Wedrén LU Rosenberg 2007 Cigarette smoking and breast cancer risk: a population-based study in Sweden Br J Cancer 97 1287 1290 17912245 10.1038/sj.bjc.6604007 1:STN:280:DC%2BD2snktFyrsw%3D%3D (Pubitemid 350035804)
17. P Vestergaard L Rejnmark L Mosekilde 2006 Socioeconomic aspects of fractures within universal public healthcare: a nationwide case-control study from Denmark Scand J Public Health 34 371 377 16861187 10.1080/14034940500441223 (Pubitemid 44138054)
18. V Bagnardi M Blangiardo C La Vecchia G Corrao 2001 Alcohol consumption and the risk of cancer: a meta-analysis Alcohol Res Health 25 263 270 11910703 1:STN:280:DC%2BD387nvVKrtA%3D%3D (Pubitemid 33708990)
19. C Garland E Gorham S Mohr W Grant E Giovannucci M Lipkin H Newmark M Holick F Garland 2007 Vitamin D and prevention of breast cancer: pooled analysis J Steroid Biochem Mol Biol 103 708 711 17368188 10.1016/j.jsbmb.2006.12.007 1:CAS:528:DC%2BD2sXjt1Wnt7o%3D (Pubitemid 46420519)
20. T Gissel L Rejnmark L Mosekilde P Vestergaard 2008 Intake of vitamin D and risk of breast cancer-a meta-analysis J Steroid Biochem Mol Biol 111 195 199 18590821 10.1016/j.jsbmb.2008.06.002 1:CAS:528:DC%2BD1cXhtVamtLfK
21. S Boonen D Vanderschueren X Cheng G Verbeke J Dequeker P Geusens P Broos R Bouillon 1997 Age-related (type II) femoral neck osteoporosis in men: biochemical evidence for both hypovitaminosis D-and androgen deficiency-induced bone resorption J Bone Miner Res 12 2119 2126 9421246 10.1359/jbmr.1997.12.12. 2119 1:STN:280:DyaK1c%2FotFGquw%3D%3D (Pubitemid 27524490)
22. D Bruce A St John F Nicklason P Goldswain 1999 Secondary hyperparathyroidism in patients from Western Australia with hip fracture: relationship to type of hip fracture, renal function, and vitamin D deficiency J Am Geriatr Soc 47 354 359 10078900 1:STN:280:DyaK1M7ns1OrtA%3D%3D (Pubitemid 29113852)
23. T Andersen M Madsen J Jørgensen L Mellemkjær J Olsen 1999 The Danish National hospital register Dan Med Bull 46 263 268 10421985 1:STN:280:DyaK1MzltVyrtw%3D%3D
24. J Mosbech J Jørgensen M Madsen K Rostgaard K Thornberg T Poulsen 1995 The Danish National Patient Register: evaluation of data quality [in Danish] Ugeskr Laeger 157 3741 3745 7631448 1:STN:280:DyaK2Mzlsl2msA%3D%3D
25. AR Jensen J Overgaard HH Storm 2002 Validity of breast cancer in the Danish Cancer Registry. A study based on clinical records from one county in Denmark Eur J Cancer Prev 11 359 364 12195162 10.1097/00008469-200208000-00007 1:STN:280:DC%2BD38vmtlSnsg%3D%3D (Pubitemid 34948204)
26. E Lynge 1994 Danish Cancer Registry as a resource for occupational research J Occup Med 36 1169 1173 7861259 10.1097/00043764-199411000-00001 1:STN:280:DyaK2M7msFanug%3D%3D (Pubitemid 24364075)
27. CL Shapiro A Recht 2001 Side effects of adjuvant treatment of breast cancer N Engl J Med 344 1997 2008 11430330 10.1056/NEJM200106283442607 1:CAS:528:DC%2BD3MXltFers78%3D (Pubitemid 32568155)
28. P Bruning M Pit M de Jong-Bakker A van den Ende A Hart A van Enk 1990 Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer Br J Cancer 61 308 310 2310683 10.1038/bjc.1990.58 1:STN:280: DyaK3c7otFaqsQ%3D%3D (Pubitemid 20058296)
29. I Fogelman GM Blake R Blamey M Palmer W Sauerbrei M Schumacher, et al. 2003 Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) Osteoporos Int 14 1001 1006 14530912 10.1007/s00198-003-1508-y 1:CAS:528:DC%2BD3sXpvVCms7w%3D (Pubitemid 40824271)
30. T Saarto C Blomqvist M Välimäki P Mäkelä S Sarna I Elomaa 1997 Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients J Clin Oncol 15 1341 1347 9193325 1:CAS:528:DyaK2sXivVehsr8%3D (Pubitemid 27167365)
31. JA Cauley FL Lucas LH Kuller MT Vogt WS Browner SR Cummings 1996 Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group JAMA 276 1404 1408 8892715 10.1001/jama.276.17.1404 1:STN:280:DyaK2s%2Fkslyktg%3D%3D (Pubitemid 26365846)
32. PA Newcomb A Trentham-Dietz KM Egan L Titus-Ernstoff JA Baron BE Storer, et al. 2001 Fracture history and risk of breast and endometrial cancer Am J Epidemiol 153 1071 1078 11390325 10.1093/aje/153.11.1071 1:STN:280: DC%2BD3MzislCrtA%3D%3D (Pubitemid 32493255)
33. PA Newcomb A Trentham-Dietz JM Hampton 2010 Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk Br J Cancer 102 799 802 20160722 10.1038/sj.bjc.6605555 1:CAS:528: DC%2BC3cXis1ygs70%3D
34. V Vogel J Costantino D Wickerham W Cronin R Cecchini J Atkins, et al. 2006 Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial JAMA 295 2727 2741 16754727 10.1001/jama.295.23. joc60074 1:CAS:528:DC%2BD28XmtFOltLc%3D
35. S Cummings S Eckert K Krueger D Grady T Powles J Cauley, et al. 1999 The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the more randomized trial. Multiple outcomes of raloxifene evaluation JAMA 281 2189 2197 10376571 10.1001/jama.281.23.2189 1:CAS:528:DyaK1MXktFGitL0%3D (Pubitemid 29275701)
36. LE Lévesque JA Hanley A Kezouh S Suissa 2010 Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes BMJ 340 b5087 20228141 10.1136/bmj.b5087
37. R Eastell R Hannon J Cuzick M Dowsett G Clack J Adams 2006 Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the anastrozole, tamoxifen, alone or in combination (ATAC) trial (18233230) J Bone Miner Res 21 1215 1223 16869719 10.1359/jbmr.060508 1:CAS:528: DC%2BD28XotlKrsL8%3D (Pubitemid 44128334)
38. I Persson H Adami J McLaughlin T Naessen J Fraumeni 1994 Reduced risk of breast and endometrial cancer among women with hip fractures (Sweden) Cancer Causes Control 5 523 528 7827239 10.1007/BF01831380 1:STN:280: DyaK2M7islyluw%3D%3D (Pubitemid 24335715)
39. AL Burshell J Song SA Dowsett JL Mershon PD Delmas RJ Secrest, et al. 2008 Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis Curr Med Res Opin 24 807 813 18254988 10.1185/030079908X273282 1:CAS:528:DC%2BD1cXkvValu7o%3D (Pubitemid 351428992)
40. N Pocock J Eisman J Hopper M Yeates P Sambrook S Eberl 1987 Genetic determinants of bone mass in adults: a twin study J Clin Invest 80 706 710 3624485 10.1172/JCI113125 1:STN:280:DyaL2szgvVyjtQ%3D%3D (Pubitemid 18003941)